Attached files
| file | filename |
|---|---|
| 10-K - 10-K - ALNYLAM PHARMACEUTICALS, INC. | alny-20201231.htm |
| EX-32.2 - EX-32.2 - ALNYLAM PHARMACEUTICALS, INC. | alny2020q4exhibit-322.htm |
| EX-32.1 - EX-32.1 - ALNYLAM PHARMACEUTICALS, INC. | alny2020q4exhibit-321.htm |
| EX-31.2 - EX-31.2 - ALNYLAM PHARMACEUTICALS, INC. | alny2020q4exhibit-312.htm |
| EX-31.1 - EX-31.1 - ALNYLAM PHARMACEUTICALS, INC. | alny2020q4exhibit-311.htm |
| EX-21.1 - EX-21.1 - ALNYLAM PHARMACEUTICALS, INC. | alny2020q4exhibit-211.htm |
| EX-10.20 - EX-10.20 - ALNYLAM PHARMACEUTICALS, INC. | alny2020q4exhibit-1020.htm |
| EX-10.12 - EX-10.12 - ALNYLAM PHARMACEUTICALS, INC. | alny2020q4exhibit-1012.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Forms S-3 (No. 333-238989) and S-8 (Nos. 333-236409, 333-219840, 333-207251, 333-190498, 333-226533, 333-172370, 333-165105, 333-157633, 333-148114, 333-127450 and 333-116151) of Alnylam Pharmaceuticals, Inc. of our report dated February 11, 2021 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
February 11, 2021